ReViral – Innovative therapies for viral diseases ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds. The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.
| Website | http://www.reviral.co.uk |
| Revenue | $11.8 million |
| Employees | 4 (1 on RocketReach) |
| Founded | 2011 |
| Phone | +44 20 7401 8368 |
| Industry | Biotechnology, Pharmaceuticals, Healthcare, Science and Engineering, Medical, Health Care, Therapeutics |
| Web Rank | 6 Million |
| Keywords | Viral Diseases, Antiviral Drugs, Respiratory Infections, Antiviral Research, Novel Therapeutics, Innovative Treatments, Respiratory Health, First-In-Class Drugs, Biotechnology, Emerging Biotech, Health Technology, Pharmaceutical, New Medicines, Drug Development, Clinical Trials |
| Competitors | Moderna Therapeutics, アステラス製薬(株), Emergent BioSolutions, Novavax, Halozyme, Inc., CureVac, INOVIO Pharmaceuticals, Inc., Vaxart, Inc., VBI Vaccines Inc., Bio-Matrix Scientific Group Inc +32 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular ReViral employee's phone or email?
The ReViral annual revenue was $11.8 million in 2026.
Rachel Harland is the COO of ReViral.
1 people are employed at ReViral.
The NAICS codes for ReViral are [32541, 325, 32, 3254].
The SIC codes for ReViral are [283, 28].